Hikma Pharmaceuticals PLC (LON:HIK) Receives Average Recommendation of "Buy" from Brokerages

Key Points

• Analyst consensus is “Buy”: All six covering analysts rate Hikma Pharmaceuticals positively, with an average 12-month price target of GBX 2,085.83.
• Several brokerages recently raised their targets, including Berenberg to GBX 2,100, Jefferies to GBX 2,025, Citigroup to GBX 1,870, and Deutsche Bank’s GBX 1,950 target.
• Hikma shares opened at GBX 1,599, implying substantial upside to the average analyst target; insider Tobias Hestler also purchased 7,500 shares worth £123,600.

Shares of Hikma Pharmaceuticals PLC (LON:HIK - Get Free Report) have received an average rating of "Buy" from the six analysts that are presently covering the stock, Marketbeat reports. Six research analysts have rated the stock with a buy rating. The average 1 year price target among brokerages that have updated their coverage on the stock in the last year is GBX 2,085.83.

A number of equities analysts have weighed in on HIK shares. Citigroup upped their target price on Hikma Pharmaceuticals from GBX 1,700 to GBX 1,870 and gave the stock a "buy" rating in a research note on Wednesday, August 12th. Deutsche Bank Aktiengesellschaft reissued a "buy" rating and set a GBX 1,950 price objective on shares of Hikma Pharmaceuticals in a report on Friday, August 7th. Berenberg Bank upped their price objective on shares of Hikma Pharmaceuticals from GBX 1,800 to GBX 2,100 and gave the stock a "buy" rating in a research report on Tuesday, August 11th. Finally, Jefferies Financial Group raised their target price on shares of Hikma Pharmaceuticals from GBX 1,870 to GBX 2,025 and gave the company a "buy" rating in a research note on Tuesday, August 25th.

Hikma Pharmaceuticals Trading Down 0.4%

Shares of HIK stock opened at GBX 1,599 on Friday. The company has a market capitalization of £3.34 billion, a PE ratio of 8.83, a price-to-earnings-growth ratio of 2.38 and a beta of 0.66. Hikma Pharmaceuticals has a 52-week low of GBX 1,187 and a 52-week high of GBX 1,865. The business's fifty day moving average is GBX 1,596.47 and its 200 day moving average is GBX 1,463.06. The company has a debt-to-equity ratio of 77.57, a quick ratio of 1.27 and a current ratio of 1.98.

Insider Activity at Hikma Pharmaceuticals

In related news, insider Tobias Hestler purchased 7,500 shares of the firm's stock in a transaction dated Monday, August 10th. The shares were purchased at an average price of GBX 1,648 per share, with a total value of £123,600. 22.04% of the stock is owned by insiders.

About Hikma Pharmaceuticals

At Hikma we help put better health within reach, every day. By creating high-quality medicines and making them accessible to the people who need them, we help to shape a healthier world that enriches all our communities. We help deliver this by living our culture, delivering our strategy, and acting responsibly. We are a trusted, reliable partner and dependable source of over 820+ (as of Feb 2026) high-quality generic, specialty and branded pharmaceutical products that hospitals, physicians and pharmacists need to treat their patients across North America, MENA and Europe.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.

Continue following MarketBeat

Add MarketBeat as your preferred source on Google to see our latest stories in your feed.

Add As Preferred Source